Dear Partners,

We are delighted to share with you the latest Slenyto news as part of our common efforts to support Slenyto launch;

EPA 2019

Last week, for the first time, Slenyto was exposed to the international psychiatry community in EPA congress in Warsaw, Poland. Slenyto commercial booth with its unique design was centrally located within the exhibition hall.  Among different materials that were available in Slenyto booth, the most popular were “dosing card” and “efficacy card”. As part of booth activity, to increase the awareness to Autism, Neurim made a donation to Autism Speaks organization in the name of each completer of a short quiz about Slenyto.

Slenyto was also presented in the scientific program:

  • Oral presentation by Dr. Athanasios Maras from Netherlands: “Pediatric prolonged-release melatonin for sleep in children with Autism Spectrum Disorder: implications for child behavior and caregivers quality of life”
  • Orally presented E-poster by Prof. Carmen Schroder from France: “Long-term efficacy and safety of pediatric prolonged-release melatonin for insomnia in children with Autism Spectrum Disorder”

Attendees expressed high interest in Slenyto, being amazed by Slenyto’s exceptional size as was clearly shown in the booth.

We would like to thank our partners from Finland, UK, Italy, Spain and France for attending this event and looking forward to seeing all of you in the ESCAP 2019 congress,Vienna.


Slenyto launch symposium in Germany at the DGKJP congress (Ped. Psychiatry)

The DGKJP congress is the biggest pediatric psychiatry congress in Germany and takes place every 2 years. 1,800 participants mainly from Germany, Austria and Switzerland attended the congress.

At registration every participant received a Slenyto bookmark with an invitation to visit Slenyto booth and to join the lunch symposium.
At the lunch symposium Prof. Schröder from France drew attention to the burden of insomnia that affects children with ASD as well as their whole families and Dr. Maras from the Netherlands presented Slenyto long-term efficacy and safety data. Since both speakers were involved in Slenyto clinical study, they could pass on their first hand experiences with this new and innovative medication.
90 participants choose to attend Slenyto launch symposium out of 10 additional session that took place in parallel (some with top-name experts from all around the world). The extraordinary interest in Slenyto was demonstrated by a 25 minute ongoing discussion after the lectures.

Slenyto booth was very busy with high interest in the product. Most visitor were familiar with the product and physicians that already prescribed Slenyto were very positive and satisfied with the product.

In summary, the congress was very successful and a great opportunity to further share Slenyto data, gain additional feedbacks from physicians and create new contacts.


  • Text size: A A A
  • Circadin
  • Recent news

    • Neurim Pharmaceuticals attends the EPA Congress in Warsaw, Poland, April 7-9, 2019
    • Slenyto (PedPRM) is now also available in UK!
    • Slenyto is now available in Finland
  • Partners